- Lonza has integrated its ADC technology platform into its Advanced Synthesis portfolio to strengthen support for antibody-drug conjugates (ADCs) and bioconjugates.
- The Oss, Netherlands site has expanded laboratory infrastructure and scale-up capabilities to support ADC and emerging conjugate modalities.
Lonza has strengthened its Advanced Synthesis offering to provide phase-appropriate support for the discovery and development of antibody-drug conjugates (ADCs) and other bioconjugates. The move integrates the company’s ADC technology platform into its Advanced Synthesis portfolio, expanding its contract development and manufacturing organization (CDMO) capabilities across the ADC lifecycle.
The integrated platform includes the proprietary GlycoConnect® antibody conjugation technology, HydraSpace® polar spacer technology, and a portfolio of toxSYN® linker payloads. These site-specific technologies, acquired through Lonza’s 2023 purchase of Synaffix, are designed to enhance ADC efficacy and tolerability. The offering has also been expanded to include dual-payload ADC technology, enabling the attachment of two complementary cytotoxic agents to a single antibody with controllable payload ratios.
Lonza stated that combining these technologies with its end-to-end development and contract manufacturing expertise enables customers to access integrated ADC design and scalable manufacturing from discovery through clinical supply. The strengthened framework is intended to support next-generation ADC programs targeting tumor heterogeneity and drug-induced resistance.
At its Oss, Netherlands site, Lonza has increased investment in laboratory infrastructure to broaden research and development capabilities. The site now supports ADCs and emerging bioconjugate modalities, including antibody-oligonucleotide conjugates, targeted lipid nanoparticles, and protein-protein conjugates. Expanded capabilities include small-scale bioconjugate prototyping, pilot toxicology material production, and on-site process and analytical development.
“Our recent advancements across Advanced Synthesis strengthen the support we provide to drug developers active in the field of ADCs and other bioconjugates. The expansion of the Oss site further reinforces Lonza’s global bioconjugate development and manufacturing network and underscores our dedication to continuously improving our offering and expertise in line with evolving customer and market needs.”
Jan Vertommen, Vice President, Commercial Development, Advanced Synthesis, Lonza
